MedTrace Logo

Tirzepatide in PWS, HO and GNSO

NCT06901245 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2025-09-16

No results posted yet for this study

Summary

This research study is comparing the effectiveness of a weight loss medication called Tirzepatide in young adults with Prader-Willi Syndrome and/or hypothalamic obesity, as compared to young adults with obesity that is unrelated to a genetic syndrome or underlying medical cause. These groups will be given medication for 1 year to see how weight and other health factors are effected by the medication.

Conditions

Interventions

DRUG

Tirzepatide

Subjects will take Tirzepatide for 48 weeks

Sponsors & Collaborators

  • Vanderbilt University Medical Center

    collaborator OTHER

  • Children's Hospitals and Clinics of Minnesota

    collaborator OTHER

  • Seattle Children's Hospital

    collaborator OTHER

  • Grace Kim

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
26 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-01
Primary Completion
2026-06-30
Completion
2026-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06901245 on ClinicalTrials.gov